Unwelcome surprise for Vertex as FDA slaps hold on phase 1/2 diabetes cell therapy studynews2022-05-02T14:23:05+00:00May 2nd, 2022|FierceBiotech|
Eyelid mites no match for Tarsus eye drop, as phase 3 data spurs drive to FDAnews2022-05-02T14:16:24+00:00May 2nd, 2022|FierceBiotech|
Eyelid mites no match for Tarsus eye drop, as phase 3 data spur drive to FDAnews2022-05-02T14:16:24+00:00May 2nd, 2022|FierceBiotech|
Sage, Biogen get rolling on FDA submission for depression mednews2022-05-02T13:46:11+00:00May 2nd, 2022|FierceBiotech|
Gilead follows Big Pharma peers to Dragonfly’s pond in $300M deal for natural killer cell engagersnews2022-05-02T13:10:33+00:00May 2nd, 2022|FierceBiotech|
Stealth stumbles again as age-related macular degeneration joins list of clinical trial flopsnews2022-05-02T12:53:38+00:00May 2nd, 2022|FierceBiotech|
After posting midphase data, Rezolute banks $130M to take treatment for rare disease into pivotal trialnews2022-05-02T11:40:51+00:00May 2nd, 2022|FierceBiotech|
Seeing green: Breakthrough Properties raises $3B to build in biotechnews2022-04-29T20:19:30+00:00April 29th, 2022|FierceBiotech|
Human testing for Praxis’ lead epilepsy drug held up after FDA clinical holdnews2022-04-29T16:11:58+00:00April 29th, 2022|FierceBiotech|
AstraZeneca will have to wait a little longer for fruit from $3.5B Ionis ATTR partnershipnews2022-04-29T16:04:19+00:00April 29th, 2022|FierceBiotech|
